Risk Sharing the Millennium Way
Executive Summary
Previous deals, such as those with Bayer and Monsanto, showcased Millennium Pharmaceuticals' technology integration capabilities and allowed it to leverage the value of its platform. It is now becoming more focused on using external relationships and acquisitions to forward integrate and build a product pipeline. Via a series of agreements with Aventis signed in June valued at $450 million, Millennium expects to build nothing less than the world's premier franchise in inflammation. And the agreements, including a tech transfer deal and a technology development deal along with the inflammation drug development collaboration and an equity investment by Aventis, appear to provide Millennium a way to fund drug development risk by leveraging its technology.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.